Symbols / AYTU $2.56 -3.76% Aytu BioPharma, Inc.
AYTU Chart
About
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 27.48M |
| Enterprise Value | 19.55M | Income | -24.56M | Sales | 62.64M |
| Book/sh | 1.32 | Cash/sh | 2.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 82 | IPO | — |
| P/E | — | Forward P/E | 15.06 | PEG | — |
| P/S | 0.44 | P/B | 1.93 | P/C | — |
| EV/EBITDA | 4.86 | EV/Sales | 0.31 | Quick Ratio | 0.93 |
| Current Ratio | 1.16 | Debt/Eq | 155.63 | LT Debt/Eq | — |
| EPS (ttm) | -3.44 | EPS next Y | 0.17 | EPS Growth | — |
| Revenue Growth | -6.50% | Earnings | 2026-02-03 16:00 | ROA | -0.22% |
| ROE | -109.23% | ROIC | — | Gross Margin | 66.84% |
| Oper. Margin | -12.99% | Profit Margin | -39.02% | Shs Outstand | 10.73M |
| Shs Float | 7.61M | Short Float | 5.51% | Short Ratio | 12.00 |
| Short Interest | — | 52W High | 3.07 | 52W Low | 0.96 |
| Beta | 0.28 | Avg Volume | 65.27K | Volume | 30.20K |
| Target Price | $9.67 | Recom | None | Prev Close | $2.66 |
| Price | $2.56 | Change | -3.76% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-10 | main | Ascendiant Capital | Buy → Buy | $13 |
| 2025-09-25 | main | Maxim Group | Buy → Buy | $7 |
| 2025-09-25 | main | Ascendiant Capital | Buy → Buy | $13 |
| 2025-07-01 | init | Lake Street | — → Buy | $8 |
| 2025-06-30 | init | Ascendiant Capital | — → Buy | $12 |
| 2023-08-09 | init | Maxim Group | — → Buy | $5 |
| 2023-05-31 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
- If You Invested $1,000 in Aytu Biopharma Inc (AYTU) - Stock Titan Sun, 22 Mar 2026 08
- Positive Signs As Multiple Insiders Buy Aytu BioPharma Stock - Yahoo Finance Fri, 21 Nov 2025 08
- Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st Sat, 20 Dec 2025 08
- Earnings call transcript: Aytu BioPharma Q2 2026 sees revenue dip, stock falls - Investing.com ue, 03 Feb 2026 08
- Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costs - ChartMill ue, 03 Feb 2026 08
- Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results - ACCESS Newswire ue, 03 Feb 2026 08
- Aytu BioScience Amends Warrants, Modifying Security Holder Rights - TipRanks hu, 02 Apr 2026 20
- Armistice Capital Overcomes Novel Ruling in Aytu Stock Case (1) - Bloomberg Law News hu, 14 Aug 2025 07
- Aytu BioPharma (NASDAQ: AYTU) rewrites warrant terms to restore equity - Stock Titan hu, 02 Apr 2026 20
- Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Yahoo Finance hu, 05 Feb 2026 08
- Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline - simplywall.st hu, 05 Feb 2026 08
- Ascendiant Capital raises Aytu Biosciences stock price target on Q1 beat - Investing.com Wed, 10 Dec 2025 08
- Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance hu, 13 Nov 2025 08
- New EXXUA depression drug targets MDD without sexual side effects - Stock Titan ue, 20 Jan 2026 08
- Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st Mon, 17 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
66.38
+1.84%
|
65.18
-39.31%
|
107.40
+11.10%
|
96.67
|
| Operating Revenue |
|
66.38
+1.84%
|
65.18
-39.31%
|
107.40
+11.10%
|
96.67
|
| Cost Of Revenue |
|
20.55
+27.42%
|
16.13
-60.44%
|
40.77
-8.15%
|
44.39
|
| Reconciled Cost Of Revenue |
|
18.86
+44.09%
|
13.09
-64.38%
|
36.74
-8.34%
|
40.08
|
| Gross Profit |
|
45.83
-6.57%
|
49.05
-26.38%
|
66.63
+27.44%
|
52.28
|
| Operating Expense |
|
43.29
-10.71%
|
48.49
-38.59%
|
78.96
-10.66%
|
88.39
|
| Research And Development |
|
1.33
-52.11%
|
2.77
-32.38%
|
4.09
-67.66%
|
12.66
|
| Selling General And Administration |
|
38.28
-8.93%
|
42.04
-40.01%
|
70.08
+0.28%
|
69.88
|
| Selling And Marketing Expense |
|
20.91
-5.33%
|
22.08
-46.72%
|
41.45
+7.06%
|
38.71
|
| General And Administrative Expense |
|
17.38
-12.90%
|
19.95
-30.30%
|
28.63
-8.14%
|
31.17
|
| Other Gand A |
|
17.38
-12.90%
|
19.95
-30.30%
|
28.63
-8.14%
|
31.17
|
| Total Expenses |
|
63.84
-1.20%
|
64.62
-46.03%
|
119.73
-9.82%
|
132.77
|
| Operating Income |
|
2.54
+349.03%
|
0.56
+104.58%
|
-12.33
+65.85%
|
-36.10
|
| Total Operating Income As Reported |
|
-7.83
-391.95%
|
-1.59
+90.68%
|
-17.07
+84.47%
|
-109.91
|
| EBITDA |
|
-4.67
-431.79%
|
1.41
+142.96%
|
-3.27
+87.39%
|
-25.96
|
| Normalized EBITDA |
|
7.40
-9.29%
|
8.16
+345.05%
|
-3.33
-107.23%
|
46.07
|
| Reconciled Depreciation |
|
5.38
-20.04%
|
6.72
-23.71%
|
8.81
-13.12%
|
10.15
|
| EBIT |
|
-10.04
-88.79%
|
-5.32
+56.00%
|
-12.09
+66.52%
|
-36.10
|
| Total Unusual Items |
|
-12.07
-78.66%
|
-6.75
-11949.12%
|
0.06
+100.08%
|
-72.03
|
| Total Unusual Items Excluding Goodwill |
|
-12.07
-78.66%
|
-6.75
-11949.12%
|
0.06
+100.08%
|
-72.03
|
| Special Income Charges |
|
-10.36
-276.87%
|
-2.75
+41.93%
|
-4.74
+93.57%
|
-73.63
|
| Other Special Charges |
|
—
|
0.59
|
—
|
-0.17
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
65.80
|
| Restructuring And Mergern Acquisition |
|
2.10
-2.55%
|
2.16
+322.50%
|
-0.97
+41.45%
|
-1.66
|
| Write Off |
|
8.26
|
0.00
-100.00%
|
5.71
-40.92%
|
9.66
|
| Net Income |
|
-13.56
+14.40%
|
-15.84
+7.08%
|
-17.05
+84.33%
|
-108.78
|
| Pretax Income |
|
-13.74
-32.44%
|
-10.38
+39.14%
|
-17.05
+84.34%
|
-108.89
|
| Net Non Operating Interest Income Expense |
|
-3.70
+26.80%
|
-5.06
-1.93%
|
-4.96
|
—
|
| Interest Expense Non Operating |
|
3.70
-26.80%
|
5.06
+1.93%
|
4.96
|
—
|
| Net Interest Income |
|
-3.70
+26.80%
|
-5.06
-1.93%
|
-4.96
|
—
|
| Interest Expense |
|
3.70
-26.80%
|
5.06
+1.93%
|
4.96
|
—
|
| Other Income Expense |
|
-12.58
-113.78%
|
-5.88
-2541.49%
|
0.24
+100.33%
|
-72.79
|
| Other Non Operating Income Expenses |
|
-0.51
-158.85%
|
0.87
+372.83%
|
0.18
+124.31%
|
-0.76
|
| Gain On Sale Of Security |
|
-1.70
+57.47%
|
-4.00
-183.54%
|
4.79
+198.63%
|
1.60
|
| Tax Provision |
|
0.44
-79.60%
|
2.14
|
0.00
+100.00%
|
-0.11
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-2.53
-78.66%
|
-1.42
|
0.00
+100.00%
|
-0.06
|
| Net Income Including Noncontrolling Interests |
|
-13.56
+14.40%
|
-15.84
+7.08%
|
-17.05
+84.33%
|
-108.78
|
| Net Income From Continuing Operation Net Minority Interest |
|
-14.18
-13.27%
|
-12.52
+26.57%
|
-17.05
+84.33%
|
-108.78
|
| Net Income From Continuing And Discontinued Operation |
|
-13.56
+14.40%
|
-15.84
+7.08%
|
-17.05
+84.33%
|
-108.78
|
| Net Income Continuous Operations |
|
-14.18
-13.27%
|
-12.52
+26.57%
|
-17.05
+84.33%
|
-108.78
|
| Net Income Discontinuous Operations |
|
0.62
+118.65%
|
-3.32
|
—
|
—
|
| Normalized Income |
|
-4.65
+35.29%
|
-7.18
+58.01%
|
-17.11
+53.53%
|
-36.81
|
| Net Income Common Stockholders |
|
-13.56
+14.40%
|
-15.84
+7.08%
|
-17.05
+84.33%
|
-108.78
|
| Diluted EPS |
|
-2.16
+24.48%
|
-2.86
+44.03%
|
-5.11
+93.19%
|
-75.00
|
| Basic EPS |
|
-2.16
+24.48%
|
-2.86
+44.03%
|
-5.11
+93.19%
|
-75.00
|
| Basic Average Shares |
|
6.28
+13.39%
|
5.54
+65.81%
|
3.34
+127.22%
|
1.47
|
| Diluted Average Shares |
|
6.28
+13.39%
|
5.54
+65.81%
|
3.34
+127.22%
|
1.47
|
| Diluted NI Availto Com Stockholders |
|
-13.56
+14.40%
|
-15.84
+7.08%
|
-17.05
+84.33%
|
-108.78
|
| Amortization |
|
3.68
+0.00%
|
3.68
-23.08%
|
4.79
-18.07%
|
5.84
|
| Amortization Of Intangibles Income Statement |
|
3.68
+0.00%
|
3.68
-23.08%
|
4.79
-18.07%
|
5.84
|
| Depreciation Amortization Depletion Income Statement |
|
3.68
+0.00%
|
3.68
-23.08%
|
4.79
-18.07%
|
5.84
|
| Depreciation And Amortization In Income Statement |
|
3.68
+0.00%
|
3.68
-23.08%
|
4.79
-18.07%
|
5.84
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets |
|
124.18
+5.15%
|
118.09
-13.46%
|
136.46
-0.84%
|
137.62
|
| Current Assets |
|
79.18
+27.93%
|
61.89
-12.93%
|
71.08
+18.61%
|
59.93
|
| Cash Cash Equivalents And Short Term Investments |
|
30.95
+54.71%
|
20.01
-12.96%
|
22.98
+18.72%
|
19.36
|
| Cash And Cash Equivalents |
|
30.95
+54.71%
|
20.01
-12.96%
|
22.98
+18.72%
|
19.36
|
| Receivables |
|
31.16
+32.43%
|
23.53
-18.70%
|
28.94
+33.28%
|
21.71
|
| Accounts Receivable |
|
31.16
+32.43%
|
23.53
-18.70%
|
28.94
+33.28%
|
21.71
|
| Gross Accounts Receivable |
|
32.34
+27.60%
|
25.35
-20.61%
|
31.93
+47.05%
|
21.71
|
| Allowance For Doubtful Accounts Receivable |
|
-1.19
+34.80%
|
-1.82
+39.06%
|
-2.99
|
0.00
|
| Inventory |
|
11.43
-5.82%
|
12.14
+1.22%
|
11.99
+10.56%
|
10.85
|
| Raw Materials |
|
1.11
+319.17%
|
0.27
-79.55%
|
1.30
-28.28%
|
1.81
|
| Work In Process |
|
1.38
-75.88%
|
5.72
+93.67%
|
2.96
+60.83%
|
1.84
|
| Finished Goods |
|
8.94
+45.33%
|
6.15
-20.52%
|
7.74
+7.52%
|
7.20
|
| Prepaid Assets |
|
—
|
—
|
8.05
+9.11%
|
7.38
|
| Restricted Cash |
|
—
|
—
|
—
|
0.00
|
| Assets Held For Sale Current |
|
0.00
-100.00%
|
1.12
|
—
|
—
|
| Other Current Assets |
|
5.64
+10.61%
|
5.10
-28.83%
|
7.16
-10.56%
|
8.01
|
| Total Non Current Assets |
|
45.00
-19.94%
|
56.20
-14.04%
|
65.38
-15.84%
|
77.69
|
| Net PPE |
|
1.59
+4.66%
|
1.52
-60.66%
|
3.87
-38.55%
|
6.30
|
| Gross PPE |
|
2.31
-36.74%
|
3.65
-51.70%
|
7.55
-13.39%
|
8.72
|
| Accumulated Depreciation |
|
-0.71
+66.40%
|
-2.12
+42.27%
|
-3.68
-52.04%
|
-2.42
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.27
-71.01%
|
0.94
-16.00%
|
1.12
-0.27%
|
1.13
|
| Construction In Progress |
|
—
|
0.00
-100.00%
|
0.11
|
0.00
|
| Other Properties |
|
1.87
-29.92%
|
2.67
-49.86%
|
5.32
-19.29%
|
6.59
|
| Leases |
|
0.16
+368.57%
|
0.04
-96.50%
|
1.00
+0.00%
|
1.00
|
| Goodwill And Other Intangible Assets |
|
42.20
-19.55%
|
52.45
-11.05%
|
58.97
-16.51%
|
70.63
|
| Goodwill |
|
—
|
—
|
—
|
0.00
|
| Other Intangible Assets |
|
42.20
-19.55%
|
52.45
-11.05%
|
58.97
-16.51%
|
70.63
|
| Other Non Current Assets |
|
1.20
-45.98%
|
2.23
-12.42%
|
2.54
+232.25%
|
0.77
|
| Total Liabilities Net Minority Interest |
|
105.21
+16.41%
|
90.38
-6.93%
|
97.11
+4.06%
|
93.31
|
| Current Liabilities |
|
63.06
+1.34%
|
62.23
-9.83%
|
69.02
+7.10%
|
64.44
|
| Payables And Accrued Expenses |
|
38.82
-0.51%
|
39.02
-20.08%
|
48.83
+9.38%
|
44.64
|
| Payables |
|
10.60
+2.78%
|
10.31
-23.48%
|
13.48
+22.67%
|
10.99
|
| Accounts Payable |
|
10.60
+2.78%
|
10.31
-23.48%
|
13.48
+22.67%
|
10.99
|
| Current Accrued Expenses |
|
28.22
-1.70%
|
28.71
-18.78%
|
35.35
+5.04%
|
33.65
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.13
-31.96%
|
4.60
-18.89%
|
5.67
+19.10%
|
4.76
|
| Current Debt And Capital Lease Obligation |
|
10.92
+156.82%
|
4.25
+158.01%
|
1.65
-57.84%
|
3.91
|
| Current Debt |
|
10.92
+156.82%
|
4.25
+158.01%
|
1.65
-57.84%
|
3.91
|
| Other Current Borrowings |
|
1.86
+0.00%
|
1.86
+2084.71%
|
0.09
-11.46%
|
0.10
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
3.38
-64.50%
|
9.52
+34.26%
|
7.09
+32.30%
|
5.36
|
| Total Non Current Liabilities Net Minority Interest |
|
42.15
+49.72%
|
28.15
+0.21%
|
28.09
-2.71%
|
28.87
|
| Long Term Debt And Capital Lease Obligation |
|
10.89
+0.17%
|
10.88
-26.07%
|
14.71
+3.04%
|
14.28
|
| Long Term Debt |
|
10.89
+0.17%
|
10.88
-26.07%
|
14.71
+3.04%
|
14.28
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
4.92
+8.59%
|
4.53
-35.07%
|
6.97
-45.50%
|
12.80
|
| Stockholders Equity |
|
18.97
-31.57%
|
27.72
-29.58%
|
39.36
-11.17%
|
44.31
|
| Common Stock Equity |
|
18.97
-31.57%
|
27.72
-29.58%
|
39.36
-11.17%
|
44.31
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
8.98
+50.30%
|
5.97
+8.26%
|
5.52
+186.02%
|
1.93
|
| Ordinary Shares Number |
|
8.98
+50.30%
|
5.97
+8.26%
|
5.52
+186.02%
|
1.93
|
| Additional Paid In Capital |
|
352.50
+1.38%
|
347.69
+1.22%
|
343.49
+3.65%
|
331.39
|
| Retained Earnings |
|
-333.54
-4.24%
|
-319.97
-5.21%
|
-304.13
-5.94%
|
-287.08
|
| Total Equity Gross Minority Interest |
|
18.97
-31.57%
|
27.72
-29.58%
|
39.36
-11.17%
|
44.31
|
| Total Capitalization |
|
29.86
-22.63%
|
38.59
-28.62%
|
54.07
-7.71%
|
58.59
|
| Working Capital |
|
16.11
+4881.90%
|
-0.34
-116.33%
|
2.06
+145.73%
|
-4.51
|
| Invested Capital |
|
40.78
-4.82%
|
42.84
-23.10%
|
55.72
-10.85%
|
62.50
|
| Total Debt |
|
21.82
+44.19%
|
15.13
-7.53%
|
16.36
-10.05%
|
18.19
|
| Capital Lease Obligations |
|
—
|
—
|
—
|
—
|
| Net Tangible Assets |
|
-23.23
+6.07%
|
-24.74
-26.13%
|
-19.61
+25.49%
|
-26.32
|
| Tangible Book Value |
|
-23.23
+6.07%
|
-24.74
-26.13%
|
-19.61
+25.49%
|
-26.32
|
| Current Provisions |
|
6.81
+40.96%
|
4.83
-16.36%
|
5.78
+0.12%
|
5.77
|
| Derivative Product Liabilities |
|
26.33
+106.62%
|
12.74
+99.05%
|
6.40
+256.51%
|
1.80
|
| Line Of Credit |
|
9.06
+278.41%
|
2.40
+53.23%
|
1.56
-59.01%
|
3.81
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-1.94
-39.55%
|
-1.39
+72.94%
|
-5.13
+82.21%
|
-28.82
|
| Cash Flow From Continuing Operating Activities |
|
-1.94
-39.55%
|
-1.39
+72.94%
|
-5.13
+82.21%
|
-28.82
|
| Net Income From Continuing Operations |
|
-13.56
+14.40%
|
-15.84
+7.08%
|
-17.05
+84.33%
|
-108.78
|
| Depreciation Amortization Depletion |
|
5.38
-20.04%
|
6.72
-23.71%
|
8.81
-13.12%
|
10.15
|
| Depreciation |
|
5.38
-20.04%
|
6.72
-23.71%
|
8.81
-13.12%
|
10.15
|
| Depreciation And Amortization |
|
5.38
-20.04%
|
6.72
-23.71%
|
8.81
-13.12%
|
10.15
|
| Other Non Cash Items |
|
1.11
-74.82%
|
4.42
+1198.01%
|
-0.40
+78.17%
|
-1.85
|
| Stock Based Compensation |
|
0.58
-75.73%
|
2.37
-60.75%
|
6.05
+15.21%
|
5.25
|
| Provisionand Write Offof Assets |
|
—
|
—
|
—
|
-0.07
|
| Asset Impairment Charge |
|
8.59
+622.29%
|
1.19
-85.24%
|
8.06
-89.62%
|
77.64
|
| Operating Gains Losses |
|
1.70
-61.33%
|
4.40
+191.88%
|
-4.79
-1184.99%
|
-0.37
|
| Gain Loss On Investment Securities |
|
1.70
-57.47%
|
4.00
+183.54%
|
-4.79
-2562.78%
|
-0.18
|
| Change In Working Capital |
|
-5.73
-23.03%
|
-4.66
+19.64%
|
-5.80
+46.62%
|
-10.86
|
| Change In Receivables |
|
-7.63
-246.68%
|
5.20
+172.71%
|
-7.15
-209.49%
|
6.53
|
| Changes In Account Receivables |
|
-7.63
-246.68%
|
5.20
+172.71%
|
-7.15
-209.49%
|
6.53
|
| Change In Inventory |
|
0.38
+107.92%
|
-4.82
-33.58%
|
-3.61
-377.83%
|
1.30
|
| Change In Prepaid Assets |
|
-0.45
-237.08%
|
0.33
-61.11%
|
0.85
-62.03%
|
2.23
|
| Change In Payables And Accrued Expense |
|
1.17
+110.44%
|
-11.24
-287.63%
|
5.99
+128.56%
|
-20.97
|
| Change In Accrued Expense |
|
0.89
+109.67%
|
-9.16
-354.12%
|
3.60
+127.12%
|
-13.29
|
| Change In Payable |
|
0.29
+113.82%
|
-2.08
-187.08%
|
2.38
+131.04%
|
-7.68
|
| Change In Account Payable |
|
0.29
+113.82%
|
-2.08
-187.08%
|
2.38
+131.04%
|
-7.68
|
| Change In Other Working Capital |
|
0.79
-86.50%
|
5.87
+413.46%
|
-1.87
-3844.00%
|
0.05
|
| Investing Cash Flow |
|
-2.56
-678.12%
|
-0.33
-181.20%
|
-0.12
+96.40%
|
-3.25
|
| Cash Flow From Continuing Investing Activities |
|
-2.56
-678.12%
|
-0.33
-181.20%
|
-0.12
+96.40%
|
-3.25
|
| Net PPE Purchase And Sale |
|
0.44
+233.74%
|
-0.33
|
—
|
—
|
| Purchase Of PPE |
|
-0.23
+30.70%
|
-0.33
|
—
|
—
|
| Sale Of PPE |
|
0.67
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-3.23
-881.16%
|
-0.33
|
—
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
-0.01
+99.84%
|
-3.18
|
| Purchase Of Business |
|
—
|
—
|
-0.01
+99.84%
|
-3.18
|
| Net Intangibles Purchase And Sale |
|
-3.00
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-3.00
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
-0.33
-181.20%
|
-0.12
-67.14%
|
-0.07
|
| Financing Cash Flow |
|
15.44
+1323.69%
|
-1.26
-114.23%
|
8.87
+479.80%
|
1.53
|
| Cash Flow From Continuing Financing Activities |
|
15.44
+1323.69%
|
-1.26
-114.23%
|
8.87
+479.80%
|
1.53
|
| Net Issuance Payments Of Debt |
|
6.67
+452.80%
|
-1.89
+19.44%
|
-2.35
+55.07%
|
-5.22
|
| Issuance Of Debt |
|
8.53
-38.37%
|
13.83
|
0.00
-100.00%
|
15.00
|
| Repayment Of Debt |
|
-1.86
+88.19%
|
-15.72
-570.16%
|
-2.35
+88.40%
|
-20.22
|
| Long Term Debt Issuance |
|
1.86
-85.72%
|
13.00
|
0.00
-100.00%
|
15.00
|
| Long Term Debt Payments |
|
-1.86
+88.19%
|
-15.72
-16277.08%
|
-0.10
+99.40%
|
-16.10
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-2.72
-2735.42%
|
-0.10
+91.28%
|
-1.10
|
| Short Term Debt Issuance |
|
6.67
+701.44%
|
0.83
|
—
|
152.24
|
| Short Term Debt Payments |
|
—
|
—
|
-2.25
+45.40%
|
-4.12
|
| Net Short Term Debt Issuance |
|
6.67
+701.44%
|
0.83
+136.98%
|
-2.25
+45.40%
|
-4.12
|
| Net Common Stock Issuance |
|
14.84
+328.04%
|
3.47
-77.74%
|
15.57
+33.19%
|
11.69
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
—
|
| Net Other Financing Charges |
|
-6.07
-113.63%
|
-2.84
+34.86%
|
-4.36
+11.82%
|
-4.94
|
| Changes In Cash |
|
10.95
+467.44%
|
-2.98
-182.18%
|
3.62
+111.87%
|
-30.54
|
| Beginning Cash Position |
|
20.01
-12.96%
|
22.98
+18.72%
|
19.36
-61.20%
|
49.90
|
| End Cash Position |
|
30.95
+54.71%
|
20.01
-12.96%
|
22.98
+18.72%
|
19.36
|
| Free Cash Flow |
|
-5.17
-200.82%
|
-1.72
+66.52%
|
-5.13
+82.21%
|
-28.82
|
| Interest Paid Supplemental Data |
|
2.82
-30.13%
|
4.04
+5.95%
|
3.81
+21.09%
|
3.15
|
| Income Tax Paid Supplemental Data |
|
1.42
-11.75%
|
1.61
|
0.00
|
—
|
| Common Stock Issuance |
|
14.84
+328.04%
|
3.47
-77.74%
|
15.57
+33.19%
|
11.69
|
| Issuance Of Capital Stock |
|
14.84
+328.04%
|
3.47
-77.74%
|
15.57
+33.19%
|
11.69
|
| Sale Of Business |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-02 View
- 10-Q2026-02-03 View
- 8-K2026-02-03 View
- 8-K2026-01-20 View
- 8-K2025-12-10 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 42025-10-07 View
- 42025-10-07 View
- 42025-10-07 View
- 42025-10-07 View
- 42025-10-07 View
- 42025-10-07 View
- 42025-10-07 View
- 42025-10-07 View
- 10-K2025-09-23 View
- 8-K2025-09-23 View
- 8-K2025-08-07 View
- 8-K2025-06-23 View
- 8-K2025-06-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|